ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
[Predictive value of
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPatients with recurrent tongue squamous cell carcinoma (RTSCC) receiving nonsurgical treatment have a poor prognosis. This study aims to identify independent factors associated with survival in these patients and to evaluate the effects of treatment response on survival outcomes.
methodsPatients with RTSCC who received nonsurgical treatment at Hunan Cancer Hospital between January 2017 and July 2024 were retrospectively enrolled. Pretreatment metabolic parameters derived from
resultsA total of 93 patients with RTSCC were included. The follow-up duration ranged from 2 to 81 months, with a median of 38 months. Disease progression occurred in 72 patients, and 66 patients died. PFS ranged from 1 to 81 months, with a median of 4 months, whereas OS ranged from 2 to 81 months, with a median of 11 months. In the primary analysis, radiotherapy after recurrence was an independent protective factor for PFS (
conclusionsWhole-body total MTV and radiotherapy after recurrence have potential prognostic value for OS in patients with RTSCC receiving nonsurgical treatment. The protective association between radiotherapy after recurrence and PFS requires further validation. Patients who achieved a treatment response had better OS than those who did not respond.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.